Citius Pharma Announce Positive Topline Results For Pivotal Phase 3 Clinical Trial Of Mino-Lok
(RTTNews) - Biopharmaceutical company Citius Pharmaceuticals, Inc. (CTXR) announced Tuesday positive topline results of its pivotal Phase 3 clinical trial of Mino-Lok, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI).
The study met its primary endpoint with a statistically significant improvement in the time to failure event in patients receiving Mino-Lok compared to Control arm patients receiving clinician-directed anti-infective lock solution. The data demonstrate that Mino-Lok is well-tolerated.
The company said it looks forward to engage with the US Food and Drug Administration (FDA) to determine the optimal path forward for Mino-Lok, which is expected to offer a much-needed alternative to the current practice of catheter removal and replacement.
TSX Ends Lower Again, Sheds About 1.7% In Week
Dollar Rises To Near 7-year High
Canadian Market Remains Weak Despite Paring Some Early Losses
Swiss Market Ends Weak For 2nd Straight Day
European Stocks Close Weak As Political Tensions, Rate Uncertainty Continue To Weigh
Pound Falls Amid Risk Aversion
U.S. Consumer Sentiment Unexpectedly Drops To Seven-Month Low In June
